[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100584793":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":13,"centralContacts":17,"locations":23,"responsibleParty":40,"collaborators":7,"id":42,"slug":43,"hasResults":44,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":44,"sex":49,"minAge":50,"maxAge":7,"enrollmentInfo":51,"targetDuration":7,"studyType":54,"phases":7,"briefSummary":55,"conditions":56,"keywords":7,"overallStatus":61,"whyStopped":7,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":66,"completionDateStruct":67,"leadSponsor":69,"locationsCount":70},{"fullName":5,"class":6},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","OTHER",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"DRUG","Placenta organoids treatment","Placenta organoids in vitro treatment with heparin, aspirin, IVIG, filgrastim and metformin",[14],{"name":15,"affiliation":5,"role":16},"Chiara Tersigni, MD","PRINCIPAL_INVESTIGATOR",[18],{"name":19,"role":20,"phone":21,"phoneExt":7,"email":22},"Chiara Tersigni","CONTACT","+390630157546","chiara.tersigni@policlinicogemelli.it",[24],{"facility":25,"status":7,"city":26,"state":27,"zip":28,"country":29,"countryCode":30,"cosmosGeoPoint":31,"geoPoint":36,"contacts":37},"Fondazione Policlinico Universitario A. Gemelli IRCCS, UOC Ostetricia e Patologia Ostetrica","Rome","Lazio","00168","Italy","IT",{"type":32,"coordinates":33},"Point",[34,35],12.51133,41.89193,{"lat":35,"lon":34},[38,39],{"name":19,"role":20,"phone":21,"phoneExt":7,"email":22},{"name":15,"role":16,"phone":7,"phoneExt":7,"email":7},{"type":41,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100584793","placental-organoids-development-application-in-the-study-of-the-human-reproduction-pathophysiology-100584793",false,"NCT06893978","Placental Organoids Development: Application in the Study of the Human Reproduction Pathophysiology.","PLORG","Inclusion Criteria:\n\n* Women with uncomplicated normal term pregnancy undergoing elective cesarean section for previous uterine surgery or breech presentation of the fetus;\n* Patients with retained abortion and history of recurrent abortion sine causa at the end of the work-up of investigations performed according to ESHRE guidelines, undergoing revision of the uterine cavity;\n* Patients diagnosed with preeclampsia, defined in accordance with the definitions of ISSHP, undergoing cesarean section;\n* Patients with preterm onset, before 37 weeks gestational age, of spontaneous labor, undergoing cesarean section in labor for low weight or abnormal fetal presentation.\n\nExclusion Criteria:\n\n* Age \\\u003C18 years;\n* Chronic infection with HIV or HCV;\n* Ongoing malignant neoplasms;\n* Multiple pregnancies;\n* Inability to provide informed informed consent.","FEMALE","18 Years",{"count":52,"type":53},20,"ESTIMATED","OBSERVATIONAL","Placental organoids represent an in vitro 3D reconstruction model of the human placenta and of its complex cellular organization to evaluate the pharmacological effect in terms of placentation, gene expression, protein synthesis and placental secretomics.",[57,58,59,60],"Preeclampsia","Pregnancy Loss","Preterm Birth","Healthy","NOT_YET_RECRUITING","2025-05-14",{"date":64,"type":65},"2025-05-20","ACTUAL",{"date":64,"type":53},{"date":68,"type":53},"2027-11",{"name":5,"class":6},1]